Opinion|Videos|April 9, 2025
Key Takeaways for AD Management
Author(s)Matthew Zirwas, M.D.
An expert discusses the existing gaps in atopic dermatitis (AD) management, promising areas of research to address unmet needs, and key takeaways from the discussion for the managed care audience regarding AD management.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Looking ahead, what gaps still exist in AD management, and what areas of research are most promising for addressing these unmet needs?
- Are there any key takeaways from this discussion that you would like our managed care audience to know about AD management?
Advertisement
Related to this article
In this interview, Jordan Herring, Ph.D., and Carlos E. Rodriguez-Diaz, Ph.D., MPHE, MCHES, discuss their study, which found a 16.8% increase in HIV incidence rates among Hispanic populations in antisanctuary counties after 2018 immigration policy shifts.
Metabolic dysfunction-associated steatotic liver disease (MASLD) may differ biologically from obesity-linked MASH, a mouse study suggests, with salt driving liver inflammation without obesity.
In this discussion, Ohio State economist Eric Seiber, Ph.D., explains how inconsistent claims-data definitions can skew estimates of first-episode psychosis and why standardization matters for early treatment and sustainable payment models.
CMS’ mandatory GLOBE drug model ties some Medicare Part B rebates to global prices, but cuts projected savings sharply amid shifting Part D premiums.
Bill Kerr of Avalon Heath Solutions says incorporating Z codes into CPT codes for lab and genetic testing would add needed specificity, reduce waste and possibly head off fraud.
States have to turn that information into medical frailty determinations that are clinically credible, consistent, and workable across large Medicaid populations.
A meta-analysis found steatotic liver disease in 75% of patients with sleep-disordered breathing and that CPAP lowered liver enzymes but not liver fat.
Some predicted that drugmakers might boost launch prices to make up for Medicare drug negotiations shrinking profits. Harvard researchers find no evidence of that happening so far.
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
FAQ: State PBM reform in 2026—What's new since spring
2
Final GLOBE drug model projects much smaller savings while 2027 Part D premiums split
3
New lean MASH mouse model could guide more targeted liver disease treatment in humans
4
Billing for lab tests, especially genetic tests, is a mess. Bill Kerr has ideas about how to clean it up.
5